ArticleCancer science2025

Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance.

Yidan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.